Asia's engine for advanced drug discovery 

EirGenix Strengthens U.S. East Coast Presence, Leveraging DCAT Week and TCA Multi-City Events to Expand Global CDMO Opportunities

EirGenix to Participate in PEGS Boston Summit 2026 and TCA Networking Events, Expanding Global Biologics CDMO Partnerships

Exploring Emerging Trends in Antibody Engineering, ADCs, Bispecific Antibodies, and Advanced Biologics Manufacturing at ATC 2026

Highlighting integrated biologics development and manufacturing capabilities while strengthening partnerships in the U.S. and global markets.

     Building Taiwan’s Next Global Biologics Champion     Originally Published by Pharma Boardroom April 2026

Dr. Potria Lin discusses how EirGenix leverages its dual-engine strategy—combining CDMO services and biosimilar development—to seize opportunities arising from the global biopharma supply chain realignment.SpeakerDr. Potria LinSenior Vice President & Chief Business Officer (CBO), EirGenix 

EirGenix to Participate in BIO Asia–Taiwan 2026, Expanding Global Biologics CDMO Collaboration Opportunities

Connecting with California’s Biopharma Community to Foster Strategic CDMO Partnerships and Innovation.

Connecting with Global Bioprocessing Leaders at BioProcess International 2026

Engaging with Biopharma Leaders to Explore Breakthrough Technologies Advancing Human Health and Biologics Innovation.

Strengthening Strategic Global Partnerships Through CPHI Worldwide 2026

Connecting Global Innovation with Taiwan’s Advanced Biopharmaceutical Manufacturing Ecosystem at BioJapan 2026

Advancing Global Biopharma Innovation and Partnership Opportunities at BIO-Europe (Fall) 2026